Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease

The deposition of amyloid beta A4 in the brain is a major pathological hallmark of Alzheimer's disease. Amyloid beta A4 is a peptide composed of 42 or 43 amino acid residues. In brain, it appears in the form of highly insoluble, filamentous aggregates. Using synthetic peptides corresponding to the natural beta A4 sequence as well as analog peptides, we demonstrate requirements for filament formation in vitro. We also determine aggregational properties and the secondary structure of beta A4. A comparison of amino-terminally truncated beta A4 peptides identifies a peptide spanning residues 10 to 43 as a prototype for amyloid beta A4. Infrared spectroscopy of beta A4 peptides in the solid state shows that their secondary structure consists of a beta-turn flanked by two strands of antiparallel beta-pleated sheet. Analog peptides containing a disulfide bridge were designed to stabilize different putative beta-turn positions. Limited proteolysis of these analogs allowed a localization of the central beta-turn at residues 26 to 29 of the entire sequence. Purified beta A4 peptides are soluble in water. Size-exclusion chromatography shows that they form dimers that, according to circular dichroism spectroscopy, adopt a beta-sheet conformation. Upon addition of salts, the bulk fraction of peptides precipitates and adopts a beta-sheet structure. Only a small fraction of peptides remains solubilized. They are monomeric and adopt a random coil conformation. This suggests that the formation of aggregates depends upon a hydrophobic effect that leads to intra- and intermolecular interactions between hydrophobic parts of the beta A4 sequence. This model is sustained by the properties of beta A4 analogs in which hydrophobic residues were substituted. These peptides show a markedly increased solubility in salt solutions and have lost the ability to form filaments. In contrast, the substitution of hydrophilic residues leads only to small deviations in the shape of filaments, indicating that hydrophilic residues contribute to the specificity of interactions between beta A4 peptides.

[1]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[2]  J. Pettegrew,et al.  Alzheimer's β‐Amyloid Protein Is Covalently Modified when Dissolved in Formic Acid , 1990, Journal of neurochemistry.

[3]  M J Sternberg,et al.  On the conformation of proteins: hydrophobic ordering of strands in beta-pleated sheets. , 1977, Journal of molecular biology.

[4]  A. B. Robinson,et al.  Use of Ilydrogen Fluoride in Merrifield Solid-Phase Peptide Synthesis , 1967 .

[5]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Frangione,et al.  Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x-ray diffraction pattern. , 1987, Biochemical and biophysical research communications.

[7]  J. Walker,et al.  Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Chothia,et al.  Relative orientation of close-packed beta-pleated sheets in proteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Fasman,et al.  Computed circular dichroism spectra for the evaluation of protein conformation. , 1969, Biochemistry.

[10]  K. Beyreuther,et al.  Molecular biology of Alzheimer's disease. , 1989, Annual review of biochemistry.

[11]  B. Frangione,et al.  Biology of Disease Human Amyloidosis, Alzheimer Disease and Related Disorders , 1989 .

[12]  G. Glenner.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). , 1980, The New England journal of medicine.

[13]  G. Glenner,et al.  Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[15]  P. Lansbury,et al.  Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. , 1990, Biochemistry.

[16]  G. Glenner,et al.  Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. , 1988, Biochemical and biophysical research communications.

[17]  J. Richardson,et al.  The anatomy and taxonomy of protein structure. , 1981, Advances in protein chemistry.

[18]  D. Selkoe,et al.  Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques. , 1988, Biochemical and biophysical research communications.

[19]  G. Glenner,et al.  Differences Between Vascular and Plaque Core Amyloid in Alzheimer's Disease , 1988, Journal of neurochemistry.

[20]  A. Klug,et al.  Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Hood,et al.  Automated chemical synthesis of a protein growth factor for hemopoietic cells, interleukin-3. , 1986, Science.

[22]  W. Kauzmann.  Some factors in the interpretation of protein denaturation. , 1959, Advances in protein chemistry.

[23]  D. Selkoe,et al.  Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Kamber.  Cystinpeptide aus (S‐Acetamidomethyl‐cystein)‐peptiden durch Oxydation mit Jod: Die synthese von cyclo‐L‐cystin , 1971 .

[26]  G. Multhaup,et al.  Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. , 1988, The EMBO journal.

[27]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Balaram,et al.  Stabilization of β-turn conformations in Pro-X sequences by disulphide bridging. Synthesis and solution conformations of five cyclic cystine peptides , 1984 .

[29]  J. Bandekar,et al.  Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. , 1986, Advances in protein chemistry.

[30]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[31]  R. Keller,et al.  Unusual cardioactive peptide (CCAP) from pericardial organs of the shore crab Carcinus maenas. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[33]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[34]  E. Blout,et al.  Elastase. II. Optical properties and the effects of sodium dodecyl sulfate. , 1971, Biochemistry.